Parkinson's Disease and Exercise: Slower Decline in Study

A study published October 7, 2026, in Neurology found that people with Parkinson's disease who were more physically active had slower declines in memory, thinking, and movement symptoms. The most active group, with more than 8 hours of activity per week, showed almost no average cognitive decline over time. The authors stress that this is an association, not proof that exercise slows the disease.

What happened

Researchers led by Dong-Woo Ryu, MD, PhD, of the University of Cincinnati followed 294 adults with mild to moderate Parkinson's disease for up to seven years. The average age was 66. Participants filled out questionnaires estimating weekly hours of physical activity at work, around the home, and during recreation.

Activities were sorted by intensity:

• Moderate: brisk walking, doubles tennis, leisurely swimming, and chores such as vacuuming or mowing the lawn.
• Vigorous: running, fast cycling, team sports, singles tennis, shoveling, and carrying heavy objects.

The team analyzed activity in three ways: total time in moderate or vigorous activity, overall activity volume (duration weighted by intensity), and time spent in vigorous activity alone. Based on total weekly time, participants were placed in three groups: up to 4 hours (least active), 4–8 hours (moderately active), and more than 8 hours (most active).

Each year, participants completed a cognitive assessment and a motor symptom assessment. The cognitive test was scored out of 30, and lower scores meant worse function. The motor assessment was scored from 0 to 132, and higher scores meant more severe symptoms. The average baseline motor score was 23.

Cognitive scores (estimated average change per year):

• Least active: −0.478 points
• Moderately active: −0.090 points
• Most active: −0.007 points

Motor symptom scores (estimated average change per year):

• Least active: +0.143 points (slight worsening)
• Moderately active: −0.225 points
• Most active: −0.783 points

Because higher motor scores mean worse symptoms, decreasing scores in the two more active groups mean less severe symptoms over time. The differences held after adjustment for age, sex, and disease duration. All three exposure measures were each associated with slower decline in both cognition and motor symptoms.

Why it matters

Parkinson's disease is usually taught as a movement disorder, but cognitive decline is a major driver of disability and loss of independence. Earlier work had linked physical activity mainly to motor symptoms. This study adds an association with cognition, which is why the authors describe possible "dual benefits."

The absolute differences are small, and the authors say so. They suggest that small yearly differences could add up over several years, and that any benefit may depend on staying active over time. Still, this is observational evidence. It supports further research and does not change what is known about disease-modifying treatment.

What to know for the USMLE: Parkinson's disease high-yield points

• Pathology: loss of dopaminergic neurons in the substantia nigra pars compacta, with intracellular Lewy bodies made of aggregated alpha-synuclein. Symptoms typically appear after substantial neuronal loss.
• Basal ganglia circuitry: less dopamine means less stimulation of the direct pathway (D1) and less inhibition of the indirect pathway (D2). The net result is increased inhibition of the thalamus and reduced cortical motor drive, which produces bradykinesia.
• Cardinal motor features (TRAP): resting tremor (pill-rolling), rigidity (cogwheel or lead-pipe), akinesia/bradykinesia, and postural instability. Other findings include a shuffling gait, masked facies, and micrographia.
• Non-motor features: anosmia, constipation, REM sleep behavior disorder, depression, orthostatic hypotension, and dementia. Several of these can precede the motor symptoms.
• Dementia: Parkinson disease dementia develops in the setting of established motor disease. Dementia with Lewy bodies is the usual answer when dementia appears before, or within about 1 year of, parkinsonism. Visual hallucinations and fluctuating cognition are classic for DLB.
• Pharmacology:
• Levodopa/carbidopa: carbidopa blocks peripheral dopa decarboxylase. Long-term levodopa use is associated with dyskinesias and "wearing-off" or "on-off" fluctuations.
• Dopamine agonists (pramipexole, ropinirole): associated with impulse control disorders and hallucinations.
• MAO-B inhibitors (selegiline, rasagiline) and COMT inhibitors (entacapone).
• Amantadine: helpful for dyskinesias.
• Anticholinergics (benztropine): used mainly for tremor.
• Mimics and secondary causes: drug-induced parkinsonism (e.g., antipsychotics, metoclopramide) and MPTP toxicity. Atypical parkinsonism, such as multiple system atrophy and progressive supranuclear palsy, is suggested by early autonomic failure, early falls, or vertical gaze palsy, along with poor response to levodopa.
• Study-design tip: exam questions on a study like this often test association vs causation and reverse causation. Here, patients with milder disease may simply be able to exercise more.

Limitations

The authors and the source material point to several cautions:

• Observational design. The study shows association only. It cannot show that exercise slows progression.
• Possible reverse causation. Patients whose brain function and mobility are better preserved may be more active, rather than activity preserving function.
• Self-reported activity. Hours were estimated by questionnaire, not measured directly, so some estimates may be inaccurate.
• Good baseline cognition. Participants generally had good thinking and memory skills at the start. Ryu said the results "should be interpreted with caution" for that reason.
• Small differences. The authors note that the differences between activity levels were small.
• Mild to moderate disease only. The cohort had mild to moderate Parkinson's disease, so the findings may not apply to advanced disease.
• Other details. The source does not say which specific cognitive or motor instruments were used. The 0–132 range matches the MDS-UPDRS Part III, but treat that as an inference. The source also does not explain why motor scores fell in the more active groups. Do not over-interpret it.

The study was funded by the Gardner Family Foundation and the Precision Medicine in Neurodegenerative Diseases Fund.

FAQ

Does exercise slow Parkinson's disease progression?

This study cannot answer that. It found that higher activity was associated with slower cognitive and motor decline. Researchers say more work is needed to determine whether exercise itself slows progression.

How much activity was linked to the best outcomes?

The group reporting more than 8 hours of weekly activity had nearly unchanged cognitive scores (−0.007 points per year on average). It also had the largest decrease in motor symptom scores. The moderate group (4–8 hours) also fared better than the least active group (up to 4 hours). This describes group averages in one study, not a recommendation for any individual.

What is the difference between Parkinson disease dementia and dementia with Lewy bodies?

Both involve Lewy body pathology. The usual USMLE distinction is timing. If cognitive impairment appears before or within about a year of motor parkinsonism, think dementia with Lewy bodies. If it appears well after established motor disease, think Parkinson disease dementia.

Key takeaways

• In 294 adults with mild to moderate Parkinson's disease followed for up to seven years, higher self-reported physical activity was associated with slower cognitive and motor decline.
• The study is observational and based on self-reported activity, and the differences were small. It cannot prove that exercise changes disease progression, and reverse causation is possible.
• For the USMLE, focus on substantia nigra degeneration, Lewy bodies, basal ganglia pathways, motor and non-motor features, the PDD vs DLB timing rule, and levodopa-related pharmacology.